Tarsus
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
17700 Laguna Canyon Rd Ste 400, Irvine, ...Phone Number
(949) 418-1801Website
www.tarsusrx.comRevenue
$606.3 MillionStock Symbol
TARSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
2
1
1
1
About Tarsus
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for diseases with significant unmet patient needs. Its work initially centers on eye care, with a focus on conditions such as Demodex blepharitis and ocular rosacea, while also exploring therapies for Lyme disease prevention. The company combines scientific research, clinical development, and patient-focused innovation to advance novel treatment options and address complex healthcare challenges.Explore more
Tarsus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tarsus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Tarsus has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Tarsus
Click to see if Tarsus had a recent Job posting/layoffs
Tarsus, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tarsus is spiking on competitors!
Earning: See what the market has to say on Tarsus recently announced quarterly report
Product Launch: Get notified when Tarsus launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Tarsus has new funding data
Recommended Actions
Find VP level buyers at Tarsus
Find 2 more new buyers
Compare Similar Companies to Tarsus
Compare insights from companies similar to Tarsus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tarsus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tarsus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tarsus.
Tarsus financials insights
Gather financial insights about Tarsus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2022
Debt
$175M
2026
Stock/Share Issuance
$125M
Tarsus Tech Stack
A closer look at the technologies used by Tarsus
See more technologies
Most Recent Scoops
Earnings
Tarsus Pharmaceuticals has updated its full-year 2026 Xtempi net product sales guidance to $685 million to $705 million, increased from prior guidance of $670 million to $700 million, with tempered growth expected in Q3 and more robust growth anticipated in Q4 supported by year-end patient dynamics.
Earnings, Finance
Open Position
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Tarsus News & Media
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline - AllSci
Tarsus Pharmaceuticals raises $125M in PIPE financing to fund Alkeus acquisition and expand eye care pipeline. Learn about the oversubscribed offering.Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-yearTarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tarsus
Sign Up For FreeTo access detailed company insights
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for diseases with significant unmet patient needs. Its work initially centers on eye care, with a focus on conditions such as Demodex blepharitis and ocular rosacea, while also exploring therapies for Lyme disease prevention. The co... Read More
